VANCOUVER, BC and BOSTON, MA, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:

Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety

VANCOUVER, BC and BOSTON, MA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:

BlackRock Inc. bought a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ: XENE) during t

Xenon Pharmaceuticals (XENE) is upgraded to "Strong Buy" following positive phase 3 X-TOLE2 results

RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperfor

10x Genomics reported second-quarter revenue of $151 million, including $1.6 million in license and

Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, wh

Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript

Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(1.11) per share which beat the an

NDA submission for azetukalner on track for Q3 2026  following pre-NDA meeting with FDA Phase 3 X-TO

VANCOUVER, BC and BOSTON, MA, July 31, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:

VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:

Bank of New York Mellon Corp grew its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ: XENE

Castleark Management LLC purchased a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ: X

Xenon Pharmaceuticals (XENE) is transitioning into a late-stage, cash-rich neuroscience company with

VANCOUVER, British Columbia and BOSTON, MA, July 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals

Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahe

XENE's shares climb 22% in six months as azetukalner delivers strong phase III epilepsy data and adv

VANCOUVER, British Columbia and BOSTON, MA, May 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals I

JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight an

Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epile

Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Tran

JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight an

Xenon Pharmaceuticals NASDAQ: XENE said it is preparing to submit a new drug application to the U.S.

RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperfor

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lower

Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-y

Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-T

Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and l

Analysts change outlook on top names: Truist cut KFY price target, Oppenheimer raised AZO target, B.

Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overwei

Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and r

Deutsche Bank analyst David Hoang maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and ra

HC Wainwright & Co. analyst Douglas Tsao maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a

Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated

US stocks fell, Nasdaq down 1%, Dow down 1.71%, S&P 500 down 1.43%. Energy shares down 0.1%, con

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and raise

Baird analyst Brian Skorney maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and r

Biohaven shares rose in premarket trading after Xenon's Phase 3 epilepsy study showed strong sei

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer

US stocks fall as Dow Jones drops over 1% on Monday, while NASDAQ and S&P 500 also decline. Korn

Xenon Pharmaceuticals shares surge after Phase 3 data show strong seizure reduction for azetukalner,

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and raise

Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overwei

Wolfe Research analyst Rudy Li initiates coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with a O

Biohaven's Phase 2 study with BHV-7000 in MDD did not meet its primary endpoint of reducing depr